- Home
- DECK vs EXEL Comparison
DECK vs EXEL Comparison
Compare DECK & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DECK | EXEL |
|---|---|---|
| Founded | 1973 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.4B | 12.7B |
| IPO Year | 1996 | 2000 |
Fundamental Metrics
Financial Performance| Metric | DECK | EXEL |
|---|---|---|
| Price | $85.42 | $55.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 23 | 21 |
| Target Price | ★ $122.45 | $46.50 |
| AVG Volume (30 Days) | 2.3M | ★ 2.4M |
| Earning Date | 05-21-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 10.90 | ★ 57.95 |
| EPS | 0.94 | ★ 1.60 |
| Revenue | ★ $5,472,296,000.00 | $452,477,000.00 |
| Revenue This Year | $11.16 | $13.61 |
| Revenue Next Year | $6.96 | $13.13 |
| P/E Ratio | $92.64 | ★ $34.15 |
| Revenue Growth | ★ 9.76 | N/A |
| 52 Week Low | $78.91 | $33.76 |
| 52 Week High | $125.45 | $57.57 |
Technical Indicators
Market Signals| Indicator | DECK | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 35.37 | 53.46 |
| Support Level | N/A | $54.30 |
| Resistance Level | $105.61 | $57.12 |
| Average True Range (ATR) | 2.13 | 1.27 |
| MACD | -0.17 | 0.21 |
| Stochastic Oscillator | 6.33 | 74.24 |
Price Performance
Historical ComparisonAbout DECK Deckers Outdoor Corporation
Founded in 1973, California-based Deckers designs and sells casual and performance footwear, apparel, and accessories. In fiscal 2026, Ugg and Hoka accounted for 50% and 47% of total sales, respectively. The firm also markets a niche sandal brand Teva. Deckers produces most of its sales through wholesale partnerships but also operates e-commerce in more than 50 countries and has more than 200 company-operated stores, about half of which are outlets. The firm generated 58% of its fiscal 2026 sales in the United States.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.